A multicenter clinical trial reported that intramuscular sotrovimab matched intravenous administration in reducing viral load among outpatients with early mild-to-moderate COVID-19. The result supports simpler administration logistics without sacrificing the virologic clearance endpoint in the early treatment window, which may matter for real-world delivery models.
Get the Daily Brief